Menu Search
Equities

Rohto Pharmaceutical Co Ltd

4527N:MEX

Rohto Pharmaceutical Co Ltd

Actions
  • Price (MXN)320.18
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Apr 12 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Rohto Pharmaceutical Co Ltd grew revenues 13.48% from 238.66bn to 270.84bn while net income improved 17.29% from 26.38bn to 30.94bn.
Gross margin57.38%
Net profit margin9.71%
Operating margin12.51%
Return on assets7.37%
Return on equity11.22%
Return on investment10.29%
More ▼

Cash flow in JPYView more

In 2024, Rohto Pharmaceutical Co Ltd increased its cash reserves by 11.42%, or 8.87bn. The company earned 34.27bn from its operations for a Cash Flow Margin of 12.65%. In addition the company used 16.32bn on investing activities and also paid 13.78bn in financing cash flows.
Cash flow per share159.17
Price/Cash flow per share18.23
Book value per share1,109.16
Tangible book value per share855.07
More ▼

Balance sheet in JPYView more

Rohto Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 14.42%, a higher figure than the previous year's 2.50%.
Current ratio1.84
Quick ratio1.29
Total debt/total equity0.176
Total debt/total capital0.1442
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)0.89%
Div growth rate (5 year)18.61%
Payout ratio (TTM)25.94%
EPS growth(5 years)25.85
EPS (TTM) vs
TTM 1 year ago		-8.45
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.